FDA Approves New Therapy for HRR-Mutated Prostate Cancer
Episode 1 min 48s

FDA Approves New Therapy for HRR-Mutated Prostate Cancer

Welcome to Onco Life Centre Podcast. This episode explains how the FDA's October 26, 2026 decision opens an existing two-drug combination to earlier use in metastatic prostate cancer with homologous recombination repair gene mutations. We walk through who qualifies, what the trial found, and which risks matter. You'll learn: - What the FDA decision on October 26, 2026 changed for metastatic prostate cancer - Who qualifies, including the cancer stage terms and the HRR gene mutation requireme...

Community discussion